Advertisement
Collaboration › Details
CRISPR Therapeutics–Leucadia: investor conference, 201710 supply service CRISPR presents at Jefferies Gene Technology Investor Summit in New York
Period | 2017-10-12 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | CRISPR Therapeutics AG (Nasdaq: CRSP) | |
Group | CRISPR Therapeutics (Group) | |
Partner, 2nd | Jefferies LLC | |
Group | Leucadia (Group) | |
Product | genomic technology | |
Person | Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO) | |
Person 2 | Brinzey, Christopher F. (Chris) (Westwicke Partners 201703) | |
CRISPR Therapeutics AG. (10/4/17). "Press Release: CRISPR Therapeutics to Present at Investor Conferences in October". Zug & Cambridge, MA.
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., President of CRISPR Therapeutics, is scheduled to present at two upcoming Investor Conferences in October.
Event: Chardan Gene Therapy Conference
Date: Tuesday, October 10, 2017
Time: 2:00 PM EDT
Event: Jefferies Gene Technology Investor Summit
Date: Thursday, October 12, 2017
Time: 11:10 AM EDT
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
MEDIA CONTACTS:
Jennifer Paganelli
WCG on behalf of CRISPR
+1 347-658-8290 jpaganelli@wcgworld.com
INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
+1 339-970-2843 chris.brinzey@westwicke.com
Record changed: 2017-10-14 |
Advertisement
More documents for CRISPR Therapeutics (Group)
- [1] CRISPR Therapeutics AG. (2/13/24). "Press Release: CRISPR Therapeutics Announces $280 Million Registered Direct Offering". Zug & Boston, MA....
- [2] CRISPR Therapeutics AG. (2/13/24). "Press Release: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)". Z...
- [3] CRISPR Therapeutics AG. (1/3/24). "Press Release: CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Zug & Boston, MA....
- [4] CRISPR Therapeutics AG. (6/13/23). "Pressemitteilung: CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference". Zug & Cambridge, MA....
- [5] CRISPR Therapeutics AG. (4/13/23). "Press Release: CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference". Zug & Cambridge, MA....
- [6] CRISPR Therapeutics AG. (4/3/23). "Press Release: CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalas...
- [7] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
- [8] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....
- [9] CRISPR Therapeutics AG. (3/13/23). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Boston, MA....
- [10] CRISPR Therapeutics AG. (2/27/23). "Press Release: CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference". Zug & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top